BAYN (BAYN) News
Follow BAYN (BAYN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 68 public stories across 28 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Bayer Says Sevabertinib Approved in China for Lung Cancer
EQUITY | Nov 04, 2026, 08:04 AM UTC
M
Bayer Raises Full-Year Guidance After Third-Quarter Earnings Beat
Bayer raised its full-year guidance. Jefferies analysts said the increase appears to reflect how much third-quarter earnings exceeded expectations; strong pharmaceutical performance drove group adjusted EBITDA above expe
EQUITY | Nov 03, 2026, 02:08 PM UTC
M
Bayer Raises Full-Year Earnings Guidance as Pharma Recovers
Bayer said a recovery in its pharmaceutical business helped mitigate market pressures at its agriculture and consumer-health divisions. Shares rose 5.6% in European morning trading.
EQUITY | Nov 03, 2026, 09:06 AM UTC
M
Bayer Reports Narrower Q3 Loss and Improves Full-Year Outlook
Bayer reported a third-quarter net loss attributable to stockholders of 672 million euros, versus 963 million euros a year earlier. Loss per share was 0.69 euros, compared with 0.98 euros.
EQUITY | Nov 03, 2026, 07:42 AM UTC
M
Bayer Raises Guidance on Pharma Division Performance
EARNINGS | Nov 03, 2026, 06:58 AM UTC
M
Bayer Q3 Sales Rise on Pharmaceutical Growth; Outlook Lifted
EARNINGS | Nov 03, 2026, 06:41 AM UTC
M
Bayer Upgrades 2026 Free Cash Flow Guidance to EUR500M–EUR1.5B Outflow
EARNINGS | Nov 03, 2026, 06:37 AM UTC
L
Bayer Reports Third-Quarter Adjusted EPS of EUR 0.31
EARNINGS | Nov 03, 2026, 06:33 AM UTC
M
Bayer Reports Third-Quarter Net Loss of EUR672 Million
EQUITY | Nov 03, 2026, 06:33 AM UTC
M
Bayer Raises 2026 Earnings View
EARNINGS | Nov 03, 2026, 06:32 AM UTC
L
Bayer Reports Third-Quarter Sales of EUR10.05 Billion
EQUITY | Nov 03, 2026, 06:31 AM UTC
M
Bayer Wins China Approval for Stroke-Prevention Drug in New Class
Bayer said China authorized asundexian to prevent recurrent stroke, making it the first approved drug in a new class of blood thinners.
EQUITY | Oct 26, 2026, 11:44 AM UTC
M
China Approves Bayer’s Asundexian Blood Thinner
China’s drug regulator approved Bayer’s blood thinner asundexian, according to the report.
EQUITY | Oct 26, 2026, 10:03 AM UTC
M
Bayer Wins First Global Approval for Stroke Prevention Drug in China
Bayer said China authorized the launch of its drug to prevent recurrent stroke, marking the first global approval for a new class of medicines.
REGULATION | Oct 26, 2026, 08:43 AM UTC
L
Bayer Says Asundexian Approved in China
Bayer says China approved asundexian, describing it as the first Factor XIa inhibitor approved there.
EQUITY | Oct 26, 2026, 08:20 AM UTC
M
Bayer Phase III Trial Cuts Prostate Cancer Metastasis or Death Risk 58%
EQUITY | Oct 24, 2026, 06:30 AM UTC
M
Bayer to invest $2.2B in new Ohio pharma manufacturing site
Bayer announced plans to invest $2.2 billion in a new manufacturing facility in Ohio for its pharmaceutical business. The German group's new site in New Albany will create jobs and is part of a trend of European drugmake
EQUITY | Oct 02, 2026, 07:10 PM UTC
L
Bayer Says Bluerock Therapeutics' Investigational Cell Therapy Lemiretprocel (Opct-001) Granted Orphan Drug FDA, EMA Designations
BAYER AG XETR:BAYN
REGULATION | Sep 30, 2026, 06:35 AM UTC
L
Bayer faces trial test of remaining Roundup claims after US Supreme Court win
By Dietrich KnauthAttorneys for three cancer patients told a Missouri jury on Tuesday that Bayer's Monsanto unit failed to adequately test its Roundup weedkiller before selling it, starting a trial that could help determ
NEWS | Sep 29, 2026, 09:38 PM UTC
L
MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option
Bayer today announced the launch of MiraSOFT, a new stool softener option from the makers of MiraLAX® with the active ingredient docusate sodium designed to help gently soften hard, dry stools and support more comfortabl
NEWS | Sep 29, 2026, 01:02 PM UTC
L
Low Rhine levels hamper shipping, weighing on German industry
Water levels on the Rhine River, one of Europe's busiest shipping arteries, have fallen to another low, official data showed on Tuesday, hampering transport and production.The water level gauge at the chokepoint of Kaub
NEWS | Sep 29, 2026, 08:51 AM UTC
L
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit
By Blake BrittainA federal judge in Delaware on Monday rejected Pfizer NYSE:PFE, BioNTech NASDAQ:BNTX and Moderna's NASDAQ:MRNA requests to dismiss patent lawsuits filed against them by Bayer's XETR:BAYN Monsanto unit ov
REGULATION | Sep 28, 2026, 06:20 PM UTC
L
Bayer: FDA Grants Priority Review To Lynkuet For New Indication
LEVERKUSEN (dpa-AFX) - Bayer (BYR.L, BAY.MI, BAYN.DE) announced the FDA has accepted the supplemental New Drug Application and granted Priority Review designation for Lynkuet under investigation for the treatment of mode
REGULATION | Sep 28, 2026, 12:47 PM UTC
L
Bayer: U.S. FDA Accepts sNDA, Grants Priority Review to Lynkuet as New Indication for Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer >BAYN.XE
Bayer: U.S. FDA Accepts sNDA, Grants Priority Review to Lynkuet as New Indication for Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer >BAYN.XE
REGULATION | Sep 28, 2026, 12:01 PM UTC
L
Bayer (BAYN) Wins FDA Priority Review for Lynkuet sNDA
FDA accepted Bayer’s sNDA and granted Priority Review for Lynkuet (elinzanetant) to treat moderate to severe vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.Material DetailsContext by AI AnalystThi
REGULATION | Sep 28, 2026, 12:01 PM UTC
L
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
Today Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review designation for Lynkuet® (elinzanetant) under investi
REGULATION | Sep 28, 2026, 12:00 PM UTC
L
Weekly Recap: Sale of minority stake in contraceptives unit and €2B hybrid bond
Bayer AG (XETR:BAYN) raised roughly €3bn by selling a minority stake in its long—acting contraceptives unit to Apollo, issued €2bn of hybrid bonds (non—call 6y 5.75%, 9y 6.25%), and agreed to sell Stivarga rights to Grün
NEWS | Sep 28, 2026, 05:01 AM UTC
L
Bayer Places €2 Bln Hybrid Bonds
BAYER AG XETR:BAYN
NEWS | Sep 23, 2026, 04:12 PM UTC
L
Rallis India’s Gyanendra Shukla to head CropLife India
Pesticides manufacturers’ body CropLife India has elected Gyanendra Shukla, MD and CEO of Rallis India, a TATA Enterprise, as Chairman. Rajvir Rathi, head of agricultural affairs and policy at Bayer Crop Science, and Gir
NEWS | Sep 23, 2026, 04:11 PM UTC
M
Bayer agrees to sell Stivarga rights to Gruenenthal for up to $431M
Bayer will sell rights to its cancer drug Stivarga to Gruenenthal Group for up to 375 million euros ($430.7 million), with patent protection in the EU expiring in 2029 and in the U.S. a year later, the acquirer said.
MNA | Sep 21, 2026, 12:09 PM UTC
M
Bayer announces Series A financing to advance engineered biologicals
Bayer said it is announcing a Series A financing round to advance engineered biologicals.
EQUITY | Sep 17, 2026, 01:11 PM UTC
M
FDA approves Bayer’s Kerendia for chronic kidney disease in type 1 diabetes
Bayer said the FDA approved Kerendia (finerenone) to treat adult patients with chronic kidney disease associated with type 1 diabetes, its third approved indication in the U.S.
REGULATION | Sep 17, 2026, 07:21 AM UTC
M
FDA approves Bayer’s KERENDIA (finerenone) for CKD with type 1 diabetes
Bayer said the FDA approved KERENDIA (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) and type 1 diabetes, with the therapy expected to reduce the risk of sust
REGULATION | Sep 17, 2026, 06:39 AM UTC
M
Apollo closes €3 billion capital solution for Bayer; KKR joins
Apollo-managed funds closed a previously announced €3 billion capital solution for Bayer. KKR joins as a minority participant.
EQUITY | Sep 16, 2026, 07:01 AM UTC
L
Weekly Recap: Sevabertinib FDA approval and BAY 3670549 Ph II trial
Bayer AG (XETR:BAYN) is advancing oncology, cardiology and sustainability: sevabertinib won FDA accelerated first—line approval for HER2—mutant NSCLC after strong Phase 1/2 results, a Phase II GIRK4 inhibitor trial for a
REGULATION | Sep 14, 2026, 05:15 AM UTC
L
Voyageur Pharmaceuticals secures $1 million on first Bayer milestone
Voyageur Pharmaceuticals Ltd. said it achieved its first milestone under a non-dilutive Bayer collaboration, securing a $1 million payment.
EQUITY | Sep 10, 2026, 01:30 PM UTC
H
FDA grants accelerated approval for Bayer HYRNUO sevabertinib in HER2-mutated NSCLC
Bayer said the U.S. Food and Drug Administration granted accelerated approval for HYRNUO (sevabertinib) for first-line treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung canc
EQUITY | Sep 10, 2026, 02:21 AM UTC
M
Bayer receives FDA accelerated approval for HER2-mutant lung cancer drug
Bayer received FDA accelerated approval for sevabertinib as a first-line treatment for advanced HER2-mutant non-small cell lung cancer patients, after priority review and breakthrough therapy status.
REGULATION | Sep 09, 2026, 06:55 PM UTC
L
Bayer and Neste plan to expand renewable fuel feedstock
Bayer and Neste aim to expand feedstock for renewable diesel and sustainable aviation fuel.
EQUITY | Sep 09, 2026, 12:05 PM UTC
L
Bayer and Neste enter commercial agreement
Bayer and Neste entered a commercial agreement.
EQUITY | Sep 09, 2026, 12:04 PM UTC
L
Bayer, Neste to Jointly Scale Winter Canola for Biofuels Production
Bayer, Neste to Jointly Scale Winter Canola for Biofuels Production
EQUITY | Sep 09, 2026, 12:02 PM UTC
L
Bayer and Neste close commercial agreement on Newgold® winter canola
Bayer AG and Neste have closed a commercial agreement to jointly scale Newgold® winter canola for biofuels production.
EQUITY | Sep 09, 2026, 12:01 PM UTC
L
Bayer closes commercial agreement with Neste
Bayer AG has closed a commercial agreement with Neste.
EQUITY | Sep 09, 2026, 12:01 PM UTC
M
Bayer starts Phase II study of atrial fibrillation drug candidate
Bayer has started a Phase II study of an atrial fibrillation drug candidate.
EQUITY | Sep 09, 2026, 06:34 AM UTC
M
Bayer targets €3bn+ peak with soy traits and 2029 margin
Bayer is launching commercial soy traits targeting >€3bn peak sales and expanding R&D, digital tools and biologicals to reach above-market growth and ~25% EBITDA margin by 2029, while managing Climara supply shortfall to
EQUITY | Sep 07, 2026, 05:15 AM UTC
H
Corn and Soybean Prices Are Popping. How to Play It. — Barrons.com
By Andrew BaryCommodities have rallied this year and agricultural products have joined the party in the past month.That could translate into higher food prices and overall inflation, complicating the job of the Federal R
MACRO | Sep 04, 2026, 04:55 PM UTC
L
J.P. Morgan says Bayer ag unit’s 2029 potential is underrated
J.P. Morgan analysts said the market may not fully grasp Bayer’s agricultural unit potential. In a Wednesday event, the German conglomerate reiterated its 2029 forecast for the business.
EQUITY | Sep 03, 2026, 09:56 AM UTC
L
BAYN update cites margin expansion, cash productivity and innovation growth
A comprehensive update says progress on its Five-Year Framework remains strong, with margin expansion, cash productivity and innovation-driven growth on track. Corn is cited as the main growth engine.
EQUITY | Sep 02, 2026, 11:54 PM UTC
L
BAYN reaffirms above-market growth and mid-20s EBITDA margin target for 2029
BAYN reaffirmed above-market growth and a mid-20s EBITDA margin target by 2029, citing innovation, operational efficiency and differentiated platform strategies, supported by R&D, digital integration and cost savings.
EARNINGS | Sep 02, 2026, 07:24 PM UTC
L
Bayer targets mid-20% EBITDA margin and above-market growth by 2029
Bayer says it is targeting above-market growth and a mid-20% CEBITDA margin by 2029, citing progress in margin, sales and cash flow initiatives.
EQUITY | Sep 02, 2026, 01:34 PM UTC
L
Bayer growth targets supported by new crop science launches
Bayer is launching multiple blockbuster crop science products, with two already commercialized and more planned, targeting over €3 billion in peak sales from new soy traits. AI-driven R&D and genome editing are accelerat
EARNINGS | Sep 02, 2026, 01:23 PM UTC
L
Trump administration to announce drug pricing deals
TradingView News reports the Trump administration will announce drug pricing deals.
EQUITY | Aug 31, 2026, 04:07 PM UTC
L
Weekly Recap: Eighth Circuit upholds Roundup and Kerendia Japan filing
Weekly Recap: Eighth Circuit upholds Roundup and Kerendia Japan filing
EQUITY | Aug 31, 2026, 05:14 AM UTC
L
Bayer to present Phase III REVEAL Iodine-124 Evuzamitide PET study
Bayer announced its Phase III REVEAL study using investigational PET radiotracer Iodine 124 Evuzamitide, presented as a late-breaker at ESC 2026.
EQUITY | Aug 30, 2026, 11:45 AM UTC
L
Bayer Roundup plan survives another court detour
Bayer’s $7.25 billion Roundup plan has survived another court detour, per TradingView News.
EQUITY | Aug 28, 2026, 06:06 PM UTC
L
ESC guidelines give Class IA recommendation for finerenone in heart failure
ESC guidelines provide a Class IA recommendation for finerenone for heart failure.
EQUITY | Aug 28, 2026, 02:07 PM UTC
L
Bayer files in Japan for expanded Kerendia use
Bayer has filed in Japan for expanded use of Kerendia.
EQUITY | Aug 28, 2026, 06:34 AM UTC
M
U.S. court dismisses appeal over $7.25B Roundup deal objections
A U.S. court dismissed an appeal tied to objections to a $7.25 billion Roundup deal.
EQUITY | Aug 27, 2026, 08:25 PM UTC
M
DAX opens 0.15% higher as Infineon leads gains
The DAX Index is up 40 points, or 0.15%, on Friday, with Infineon, Adidas and RWE among the leading gainers and Qiagen, MTU Aero Engines and Bayer among the biggest losers.
EQUITY | Aug 21, 2026, 07:31 AM UTC
L
Bayer Court Hearing Rescheduled
Bayer court hearing rescheduled to Sept 14
REGULATION | Aug 06, 2026, 06:10 PM UTC